TransCon CNP
Achondroplasia (children aged 2–11)
Key Facts
Indication
Achondroplasia (children aged 2–11)
Phase
Pivotal Phase 2
Status
Active, Recruiting
Company
About Ascendis Pharma
Ascendis Pharma is a mission-driven biotech focused on developing novel therapeutics for rare endocrine diseases and oncology using its proprietary TransCon (transient conjugation) platform. The company has achieved commercial success with its first product, Skytrofa (TransCon hGH), and is advancing a deep pipeline, including late-stage candidates for achondroplasia and hypoparathyroidism. Its strategy combines internal development with strategic geographic partnerships to maximize the global potential of its platform, aiming to build a leading, fully integrated biopharmaceutical company.
View full company profile